Atlas FDA

RHA® Redensity™

FDA premarket approval P170002/S032 · decided 2023-08-31

Approval details

PMA number
P170002
Supplement
S032
Supplement type
30-Day Notice
Supplement reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Trade name
RHA® Redensity™
Generic name
Implant, dermal, for aesthetic use
Applicant
Teoxane S.A.
Date received
2023-08-11
Decision date
2023-08-31
Days to decision
20 days
Decision code
OK30
Product code
LMH
Advisory committee
General, Plastic Surgery
Expedited review
No
Location
Geneva
Statement
Extension of in-process gel holding times at two points during the manufacturing of RHA Redensity

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.